Aimei Vaccine has received approval to issue domestic shares
Aimei Vaccine（06660.HK） has received approval to issue non-publicly listed RMB common shares (i.e., domestic shares) to specific entities, according to its latest announcement on August 30.
Market analysts believe that Aimei Vaccine's issuance of domestic shares this time is for non-tradable publicly listed shares, raising funds in RMB from domestic primary market investors. These funds are highly likely to exit through an A-share listing. This indicates the company's imminent plan to return to the A-share market, following its H-share listing in October last year, and reflects the strategic vision moving into the implementation stage.
Upon closer scrutiny, it becomes evident that Aimei Vaccine has achieved significant research and development breakthroughs with several innovative vaccines this year.
On March 8 this year, Aimei Vaccine announced plans to raise funds based on specific authorization, earmarked for constructing new production facilities for the bivalent hand, foot, and mouth disease vaccine EV71-CA16, as well as developing mRNA vaccines for COVID-19 variants (including but not limited to single and multivalent vaccines for the Omicron BA.5 variant); developing a multivalent pneumococcal conjugate vaccine; and supplementing operating capital and general corporate purposes.
In February and March this year, Aimei Vaccine was included in the Hang Seng Composite Index and quickly became part of the stock connect programs between Hong Kong and mainland China, significantly increasing the company's market exposure and gradually expanding its investor base.
For investors, especially those in mainland China, what are the investment values of this leading domestic vaccine enterprise?
Aimei Vaccine currently has eight commercialized vaccine products in the Chinese market targeting six diseases (rabies, hepatitis B, hepatitis A, mumps, hemorrhagic fever with renal syndrome, and meningococcal disease). In the areas of hepatitis B and rabies vaccines, Aimei Vaccine has established an absolute dominance.
Based on the 2021 licensing volume, Aimei Vaccine is the largest supplier of hepatitis B vaccines globally and in China, as well as the second-largest producer of human rabies vaccines worldwide and in China.
Currently, Aimei Vaccine possesses all five validated human vaccine technology platforms globally (bacterial vaccine platform technology, viral vaccine platform technology, genetic engineering vaccine platform technology, combined vaccine platform technology, and mRNA vaccine platform technology). Particularly in the deployment of the mRNA technology platform, Aimei Vaccine has a strong advantage.
Within the mRNA technology platform, Aimei not only has the first domestic bivalent broad-spectrum mRNA vaccine targeting the Omicron BA.5 variant, which has entered phase III clinical trials, serving as the best validation of its platform strength. Aimei's mRNA technology platform vaccines have obtained a total of eight domestic and international clinical approvals. Furthermore, its domestic first non-COVID mRNA vaccine, namely the mRNA rabies vaccine, has already applied for clinical trial acceptance from the Center for Drug Evaluation (CDE).
In the future, Aimei Vaccine will continue to have numerous varieties such as RSV and tumor vaccines on the lucrative track, demonstrating immense potential applications in the mRNA technology platform.
Additionally, within Aimei's rich product pipeline, with breakthroughs in the R&D and commercialization of several heavyweight products such as the 13-valent pneumococcal polysaccharide conjugate vaccine, the quadrivalent meningococcal polysaccharide conjugate vaccine, and the bivalent EV71-CA16 hand, foot, and mouth disease vaccine, when combined with capital recognition and support, investors have sufficient reasons to anticipate Aimei Vaccine delivering innovative products with higher safety and better immunogenicity to humanity.
It is expected that in five years, Aimei will become a world-class vaccine enterprise with more than 20 approved and marketed vaccines, including over eight heavyweight vaccines, truly unleashing the advantages of a leading enterprise. As a leading enterprise in the domestic vaccine industry, Aimei Vaccine's return to the A-share market will undoubtedly attract high market attention.
Market analysts believe that Aimei Vaccine's issuance of domestic shares this time is for non-tradable publicly listed shares, raising funds in RMB from domestic primary market investors. These funds are highly likely to exit through an A-share listing. This indicates the company's imminent plan to return to the A-share market, following its H-share listing in October last year, and reflects the strategic vision moving into the implementation stage.
Upon closer scrutiny, it becomes evident that Aimei Vaccine has achieved significant research and development breakthroughs with several innovative vaccines this year.
On March 8 this year, Aimei Vaccine announced plans to raise funds based on specific authorization, earmarked for constructing new production facilities for the bivalent hand, foot, and mouth disease vaccine EV71-CA16, as well as developing mRNA vaccines for COVID-19 variants (including but not limited to single and multivalent vaccines for the Omicron BA.5 variant); developing a multivalent pneumococcal conjugate vaccine; and supplementing operating capital and general corporate purposes.
In February and March this year, Aimei Vaccine was included in the Hang Seng Composite Index and quickly became part of the stock connect programs between Hong Kong and mainland China, significantly increasing the company's market exposure and gradually expanding its investor base.
For investors, especially those in mainland China, what are the investment values of this leading domestic vaccine enterprise?
Aimei Vaccine currently has eight commercialized vaccine products in the Chinese market targeting six diseases (rabies, hepatitis B, hepatitis A, mumps, hemorrhagic fever with renal syndrome, and meningococcal disease). In the areas of hepatitis B and rabies vaccines, Aimei Vaccine has established an absolute dominance.
Based on the 2021 licensing volume, Aimei Vaccine is the largest supplier of hepatitis B vaccines globally and in China, as well as the second-largest producer of human rabies vaccines worldwide and in China.
Currently, Aimei Vaccine possesses all five validated human vaccine technology platforms globally (bacterial vaccine platform technology, viral vaccine platform technology, genetic engineering vaccine platform technology, combined vaccine platform technology, and mRNA vaccine platform technology). Particularly in the deployment of the mRNA technology platform, Aimei Vaccine has a strong advantage.
Within the mRNA technology platform, Aimei not only has the first domestic bivalent broad-spectrum mRNA vaccine targeting the Omicron BA.5 variant, which has entered phase III clinical trials, serving as the best validation of its platform strength. Aimei's mRNA technology platform vaccines have obtained a total of eight domestic and international clinical approvals. Furthermore, its domestic first non-COVID mRNA vaccine, namely the mRNA rabies vaccine, has already applied for clinical trial acceptance from the Center for Drug Evaluation (CDE).
In the future, Aimei Vaccine will continue to have numerous varieties such as RSV and tumor vaccines on the lucrative track, demonstrating immense potential applications in the mRNA technology platform.
Additionally, within Aimei's rich product pipeline, with breakthroughs in the R&D and commercialization of several heavyweight products such as the 13-valent pneumococcal polysaccharide conjugate vaccine, the quadrivalent meningococcal polysaccharide conjugate vaccine, and the bivalent EV71-CA16 hand, foot, and mouth disease vaccine, when combined with capital recognition and support, investors have sufficient reasons to anticipate Aimei Vaccine delivering innovative products with higher safety and better immunogenicity to humanity.
It is expected that in five years, Aimei will become a world-class vaccine enterprise with more than 20 approved and marketed vaccines, including over eight heavyweight vaccines, truly unleashing the advantages of a leading enterprise. As a leading enterprise in the domestic vaccine industry, Aimei Vaccine's return to the A-share market will undoubtedly attract high market attention.
